NYSE: ENZEnzo Biochem Inc Stock
$2.17+0.04 (+1.88%)
Updated Mar 24, 2023
ENZ Price
$2.17
Fair Value Price
N/A
Market Cap
$107.77M
52 Week Low
$1.00
52 Week High
$3.06
P/E
-2.97x
P/B
3.28x
P/S
0.81x
PEG
N/A
Dividend Yield
N/A
Revenue
$81.12M
Earnings
-$35.24M
Gross Margin
23.9%
Operating Margin
-43.67%
Profit Margin
-43.4%
Debt to Equity
1.33
Operating Cash Flow
-$25M
Beta
0.51
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ENZ Overview
Enzo Biochem, Inc. manufactures and sells diagnostic and research products based on genetic engineering, biotechnology, and molecular biology to clinical laboratories, researchers, and physicians in the U.S. and internationally. Offerings include proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits used for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. Enzo Biochem was founded in 1976 and is headquartered in Farmingdale, NY.
Zen Score
–
Industry Average (30)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ENZ scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ENZ is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ENZ is good value based on its book value relative to its share price (3.28x), compared to the US Diagnostics & Research industry average (4.15x)
P/B vs Industry Valuation
ENZ is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ENZ due diligence checks available for Premium users.
Be the first to know about important ENZ news, forecast changes, insider trades & much more!
ENZ News
Valuation
ENZ price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.97x
Industry
33.03x
Market
21.37x
ENZ price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.28x
Industry
4.15x
ENZ is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ENZ's financial health
Profit margin
Revenue
$16.3M
Net Income
-$11.3M
Profit Margin
-69.3%
ENZ's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ENZ's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$76.5M
Liabilities
$43.6M
Debt to equity
1.33
ENZ's short-term assets ($36.38M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ENZ's short-term assets ($36.38M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ENZ's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ENZ's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$6.2M
Investing
-$869.0k
Financing
-$62.0k
ENZ's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ENZ vs Diagnostic & Research Stocks
Enzo Biochem Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.